Cognition Therapeutics Initiates NIA-Funded SNAP study of Elayta™ to Measure Toxic Oligomer Displacement and Clearance in Alzheimer’s Disease
PITTSBURGH, June 5, 2018 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, today announced that the first patient has been dosed in the SNAP (AβO Displacement from Synapses on Neurons in Alzheimer’s Patients) Study of Elayta™ (CT1812), Cognition’s lead candidate for […]